New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 12, 2014
15:41 EDTSQNMSequenom reports preliminary FY13 total revenue around $162M, consensus $165.45M
The company announced preliminary 2013 performance results. The company sees total revenue of approximately $162M, showing growth of approximately 81% year-over-year for 2013. Diagnostic services revenues of approximately $120M, as compared to $46.5M in 2012. Diagnostic services revenues continue to be recorded primarily as cash is received. The company added that it sees high margin stable revenue in the Sequenom Bioscience business of over $42M. Total cash, cash equivalents and marketable securities as of December 31 were approximately $71M and cash burn was reduced to approximately $14M for Q413. Unrecorded diagnostic accounts receivable are estimated to be $46M to $51M as of December 31.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use